Pharmacology of estrogens and progestogens: influence of different routes of administration
暂无分享,去创建一个
[1] W. Good,et al. A double-blind comparative study of Estraderm and Premarin in the amelioration of postmenopausal symptoms. , 1985, American journal of obstetrics and gynecology.
[2] B. Hédon,et al. Induction of amenorrhea during hormone replacement therapy: optimal micronized progesterone dose. A multicenter study. , 1994, Maturitas.
[3] R. Langer,et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. , 2003, JAMA.
[4] T. von Holst,et al. Efficacy of a new 7-day transdermal sequential estradiol/levonorgestrel patch in women. , 2002, Maturitas.
[5] I. Godsland,et al. Effects of oral and transdermal 17beta-estradiol with cyclical oral norethindrone acetate on insulin sensitivity, secretion, and elimination in postmenopausal women. , 2000, Metabolism: clinical and experimental.
[6] M. Taskinen,et al. Effects of Oral and Transdermal Estrogen Replacement Therapy on Markers of Coagulation, Fibrinolysis, Inflammation and Serum Lipids and Lipoproteins in Postmenopausal Women , 2001, Thrombosis and Haemostasis.
[7] G. Lose,et al. Oestradiol‐releasing vaginal ring versus oestriol vaginal pessaries in the treatment of bothersome lower urinary tract symptoms , 2000, BJOG : an international journal of obstetrics and gynaecology.
[8] B. Bhavnani. Estrogens and menopause: pharmacology of conjugated equine estrogens and their potential role in the prevention of neurodegenerative diseases such as Alzheimer’s , 2003, The Journal of Steroid Biochemistry and Molecular Biology.
[9] M. Hammar,et al. Endometrial effects of transdermal estradiol/norethisterone acetate. , 1992, Maturitas.
[10] G. Bolelli,et al. Targeted drug delivery in gynaecology: the first uterine pass effect. , 1997, Human reproduction.
[11] D. Wallwiener,et al. Medroxyprogesterone acetate versus norethisterone: effect on estradiol-induced changes of markers for endothelial function and atherosclerotic plaque characteristics in human female coronary endothelial cell cultures , 2002, Menopause.
[12] S. Azen,et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. , 2001, Annals of internal medicine.
[13] R. Edgren,et al. Pharmacokinetics of norethindrone: effect of particle size. , 1989, Contraception.
[14] D. Mellström,et al. Effect of oral oestriol on vaginal flora and cytology and urogenital symptoms in the post-menopause. , 1990, Maturitas.
[15] Z. Vajo,et al. Hormone Replacement Therapy Reduces Mean 24‐Hour Blood Pressure and Its Variability in Postmenopausal Women with Treated Hypertension , 2000, Menopause.
[16] J. Cline,et al. Contrasting effects of two hormone replacement therapies on the cardiovascular and mammary gland outcomes in surgically postmenopausal monkeys. , 2003, American journal of obstetrics and gynecology.
[17] E. Vittinghoff,et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.
[18] L. Skoog,et al. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. , 1996, American journal of obstetrics and gynecology.
[19] Mary Cushman,et al. Estrogen plus progestin and the risk of coronary heart disease. , 2003, The New England journal of medicine.
[20] R. Lindsay,et al. Bone loss during oestriol therapy in postmenopausal women. , 1979, Maturitas.
[21] G. Heinze,et al. Topical cyproterone acetate treatment in women with acne: a placebo-controlled trial. , 1998, Archives of dermatology.
[22] D. Sturdee,et al. Estradiol and levonorgestrel: effects on bleeding pattern when administered in a sequential combined regimen with a new transdermal patch , 2002, Climacteric : the journal of the International Menopause Society.
[23] P. Driguez,et al. Prevention of endometrial hyperplasia by progesterone during long-term estradiol replacement: influence of bleeding pattern and secretory changes. , 1993, Fertility and sterility.
[24] R. Francis,et al. The effect of estrogen dose on postmenopausal bone loss. , 1984, The New England journal of medicine.
[25] J. Vieira,et al. Comparative bioavailability study of an once-a-week matrix versus a twice-a-week reservoir transdermal estradiol delivery systems in postmenopausal women. , 1996, Maturitas.
[26] E. Schacht,et al. Performance and acceptability of intrauterine release of levonorgestrel with a miniature delivery system for hormonal substitution therapy, contraception and treatment in peri and postmenopausal women. , 2003, Maturitas.
[27] C. Stehouwer,et al. Effect of Oral and Transdermal Estrogen Replacement Therapy on Hemostatic Variables Associated With Venous Thrombosis: A Randomized, Placebo-Controlled Study in Postmenopausal Women , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[28] J. Damber,et al. Serum levels of progesterone and some of its metabolites including deoxycorticosterone after oral and parenteral administration , 1984, British journal of obstetrics and gynaecology.
[29] M. Sambhi,et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal women. , 1983, The Journal of clinical endocrinology and metabolism.
[30] Atul Kumar,et al. Current status of estrogen receptors. , 2002, Progress in drug research. Fortschritte der Arzneimittelforschung. Progres des recherches pharmaceutiques.
[31] A. Ferenczy,et al. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17β-estradiol combined with sequential 5-20 mg dydrogesterone , 2002, Climacteric : the journal of the International Menopause Society.
[32] L. Speroff,et al. The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femhrt®) on the frequency and intensity of vasomotor symptoms , 2000, Menopause.
[33] C. Coutifaris,et al. A placebo-controlled study of effects of oral progesterone on performance and mood. , 1992, British journal of clinical pharmacology.
[34] M. G. Modena,et al. Double-blind randomized placebo-controlled study of transdermal estrogen replacement therapy on hypertensive postmenopausal women. , 1999, American journal of hypertension.
[35] H. Kuhl,et al. Formation of ethinylestradiol in postmenopausal women during continuous treatment with a combination of estradiol, estriol and norethisterone acetate. , 1995, Maturitas.
[36] C. Packard,et al. Supraphysiological concentrations of estradiol in menopausal women given repeated implant therapy do not adversely affect lipid profiles. , 2002, Human reproduction.
[37] A. Breckenridge,et al. The gut wall metabolism of ethinyloestradiol and its contribution to the pre-systemic metabolism of ethinyloestradiol in humans. , 1982, British journal of clinical pharmacology.
[38] R. Langer,et al. Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial , 2003 .
[39] J. Castellsagué,et al. Hormone replacement therapy and risk of venous thromboembolism: population based case-control study , 1997, BMJ.
[40] Susan R. Johnson,et al. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. , 1996, JAMA.
[41] L. Mattsson,et al. Bioavailability of norethisterone acetate alone and in combination with estradiol administered in single or multiple oral doses to postmenopausal women. , 1999, Maturitas.
[42] L. Rabbani,et al. Oral conjugated equine estrogen increases plasma von Willebrand factor in postmenopausal women. , 2002, Journal of the American College of Cardiology.
[43] L. Shulman. Effects of progestins in different hormone replacement therapy formulations on estrogen-induced lipid changes in postmenopausal women. , 2002, The American journal of cardiology.
[44] A. Heald,et al. Progestins abrogate estrogen-induced changes in the insulin-like growth factor axis. , 2000, American journal of obstetrics and gynecology.
[45] A. LaCroix,et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. , 2003, JAMA.
[46] K. Nilsson,et al. Low-dose oestradiol in the treatment of urogenital oestrogen deficiency--a pharmacokinetic and pharmacodynamic study. , 1992, Maturitas.
[47] N. Siddle,et al. 25 mg oestradiol implants—the dosage of first choice for subcutaneous oestrogen replacement therapy? , 1992, British journal of obstetrics and gynaecology.
[48] J. Thijssen,et al. In vivo uptake and subcellular distribution of tritium-labeled estrogens in human endometrium, myometrium, and vagina. , 1983, The Journal of clinical endocrinology and metabolism.
[49] L. Dennerstein,et al. Influence of route of administration on progesterone metabolism. , 1995, Maturitas.
[50] F. al-Azzawi,et al. Trimegestone: expanding therapeutic choices for the treatment of the menopause , 2001, Expert opinion on investigational drugs.
[51] K. Grandien,et al. Printed in U.S.A. Copyright © 1997 by The Endocrine Society Comparison of the Ligand Binding Specificity and Transcript Tissue Distribution of Estrogen Receptors � and � , 2022 .
[52] L. Ignarro,et al. Effects of estrogen replacement therapy on plasma levels of nitric oxide in postmenopausal women. , 1999, American journal of obstetrics and gynecology.
[53] A. Wakatsuki,et al. Different Effects of Oral Conjugated Equine Estrogen and Transdermal Estrogen Replacement Therapy on Size and Oxidative Susceptibility of Low-Density Lipoprotein Particles in Postmenopausal Women , 2002, Circulation.
[54] P. Lavín,et al. Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. , 2004, Fertility and sterility.
[55] F. Neumann,et al. [Problems of dose finding: sexual hormones (author's transl)]. , 1977, Arzneimittel-Forschung.
[56] W. Kuhnz,et al. Pharmacokinetics of levonorgestrel in 12 women who received a single oral dose of 0.15 mg levonorgestrel and, after a washout phase, the same dose during one treatment cycle. , 1992, Contraception.
[57] H. Mcgarrigle,et al. A comparison of saliva, plasma unconjugated and plasma total oestriol levels throughout normal pregnancy , 1984, British journal of obstetrics and gynaecology.
[58] J. Eden,et al. Transdermal progesterone and its effect on vasomotor symptoms, blood lipid levels, bone metabolic markers, moods, and quality of life for postmenopausal women , 2003, Menopause.
[59] R. Punnonen. Effect of Castration and Peroral Estrogen Therapy on the Skin , 1972, Acta obstetricia et gynecologica Scandinavica. Supplement.
[60] A. Eisenfeld,et al. Estradiol is less potent than ethinyl estradiol for in vivo translocation of the mammalian liver estrogen receptor to the nucleus. , 1982, Endocrinology.
[61] M. Altındiş,et al. Hormone replacement therapy, C-reactive protein, and fibrinogen in healthy postmenopausal women. , 2003, Maturitas.
[62] I. Banović,et al. Local estrogen treatment in patients with urogenital symptoms , 2003, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.
[63] D. Archer. Percutaneous 17&bgr;-estradiol gel for the treatment of vasomotor symptoms in postmenopausal women , 2003, Menopause.
[64] L. Wiseman,et al. Transdermal estradiol/norethisterone. A review of its pharmacological properties and clinical use in postmenopausal women. , 1994, Drugs & Aging.
[65] A. Hofman,et al. Hormone replacement therapy and peripheral arterial disease: the Rotterdam study. , 2000, Archives of internal medicine.
[66] C. Timmer,et al. Pharmacokinetics of Etonogestrel and Ethinylestradiol Released from a Combined Contraceptive Vaginal Ring , 2000, Clinical pharmacokinetics.
[67] H. Kuhl,et al. Effects of progestogens on haemostasis. , 1996, Maturitas.
[68] T. Clarkson,et al. Effects of hormone replacement therapy on reactivity of atherosclerotic coronary arteries in cynomolgus monkeys. , 1994, Journal of the American College of Cardiology.
[69] E. Diczfalusy,et al. Endocrine mechanisms in fertility regulation , 1983 .
[70] M. Hammar,et al. Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women , 2002, Menopause.
[71] P. Delmas,et al. Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route. , 2004, Maturitas.
[72] Enhanced hepatic extraction of estrogens used for replacement therapy. , 1986, The Journal of clinical endocrinology and metabolism.
[73] R. Lobo,et al. Single‐Dose Pharmacokinetics of Sublingual Versus Oral Administration of Micronized 17β‐Estradiol , 1997 .
[74] R. Lindsay,et al. Prevention of Bone Mineral Loss on Postmenopausal Women by Norethisterone , 1985, Obstetrics and gynecology.
[75] M. Adams,et al. Medroxyprogesterone acetate antagonizes inhibitory effects of conjugated equine estrogens on coronary artery atherosclerosis. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[76] M. Dain,et al. Efficacy of continuous sequential transdermal estradiol and norethindrone acetate in relieving vasomotor symptoms associated with menopause. , 2000, American journal of obstetrics and gynecology.
[77] D. Philibert,et al. The pharmacological profile of a novel norpregnance progestin (trimegestone). , 1999, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[78] B. Bhavnani,et al. Metabolic clearance rate of equilin sulfate and its conversion to plasma equilin, conjugated and unconjugated equilenin, 17 beta-dihydroequilin, and 17 beta-dihydroequilenin in normal postmenopausal women and men under steady state conditions. , 1993, The Journal of clinical endocrinology and metabolism.
[79] K. Ryan,et al. Effect of estriol administration on the hypogonadal woman. , 1978, Fertility and sterility.
[80] S. Störk,et al. Effect of Oral Postmenopausal Hormone Replacement on Progression of Atherosclerosis: A Randomized, Controlled Trial , 2001, Arteriosclerosis, thrombosis, and vascular biology.
[81] A. Hofman,et al. Hormone replacement therapy and intima-media thickness of the common carotid artery: the Rotterdam study. , 1999, Stroke.
[82] D. Purdie,et al. The life and times of the estrogen receptors:an interim report , 2001, Climacteric : the journal of the International Menopause Society.
[83] H. Honjo,et al. Aromatization of norethindrone to ethynylestradiol in human adult liver [Poster 41] , 1987, Steroids.
[84] V. Brache,et al. Estradiol delivery by vaginal rings: potential for hormone replacement therapy. , 1997, Maturitas.
[85] Cristiana Maria Rocha Fidalgo dos Reis,et al. Body composition, visceral fat distribution and fat oxidation in postmenopausal women using oral or transdermal oestrogen. , 2003, Maturitas.
[86] B. Weichman,et al. Estrogen receptor activation and the dissociation kinetics of estradiol, estriol, and estrone. , 1980, Endocrinology.
[87] J. Gustafsson,et al. Update on estrogen signaling , 2003, FEBS letters.
[88] J. Torhorst,et al. Continuous, combined hormone replacement: randomized comparison of transdermal and oral preparations. , 1999, Obstetrics and gynecology.
[89] D. McDonnell,et al. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. , 1999, Endocrinology.
[90] J. Carson,et al. Risk of venous thromboembolism in users of hormone replacement therapy , 1996, The Lancet.
[91] F. Guengerich. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. , 1990, Chemical research in toxicology.
[92] M. Hammar,et al. Effect on sexual life--a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. , 1996, Maturitas.
[93] R. Moore. Livial: a review of clinical studies. , 1999, British journal of obstetrics and gynaecology.
[94] M. Hümpel,et al. In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women. , 1997, Contraception.
[95] R. Dugal,et al. Comparison of usefulness of estradiol vaginal tablets and estriol vagitories for treatment of vaginal atrophy , 2000, Acta obstetricia et gynecologica Scandinavica.
[96] M. Whitehead,et al. Symptoms of oestrogen deficiency associated with supraphysiological plasma oestradiol concentrations in women with oestradiol implants. , 1989, BMJ.
[97] P. Lopes,et al. Aerodiol versus the transdermal route: perspectives for patient preference. , 2001, Maturitas.
[98] C. Gansau,et al. Pharmacokinetics of estradiol, free and total estrone, in young women following single intravenous and oral administration of 17 beta-estradiol. , 1993, Arzneimittel-Forschung.
[99] M A Waclawiw,et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. , 1999, Circulation.
[100] M. Bixo,et al. Increase of estrogen dose deteriorates mood during progestin phase in sequential hormonal therapy. , 2003, The Journal of clinical endocrinology and metabolism.
[101] T. Staks,et al. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. , 1994, Contraception.
[102] J. Issa,et al. Methylation of the estrogen receptor gene is associated with aging and atherosclerosis in the cardiovascular system. , 1999, Cardiovascular research.
[103] M. Stern. Pharmacology of conjugated oestrogens. , 1982, Maturitas.
[104] P. Kenemans,et al. Oral, more than transdermal, estrogen therapy improves lipids and lipoprotein(a) in postmenopausal women: a randomized, placebo-controlled study , 2003, Menopause.
[105] J. Thalabard,et al. Biological effects of estradiol-17 beta in postmenopausal women: oral versus percutaneous administration. , 1986, The Journal of clinical endocrinology and metabolism.
[106] F. Neumann. The physiological action of progesterone and the pharmacological effects of progestogens--a short review. , 1978, Postgraduate medical journal.
[107] J. Cline,et al. Effects of 17α-dihydroequilenin sulfate on atherosclerotic male and female rhesus monkeys , 1996 .
[108] J. H. Clark,et al. Estrogen-induced uterine responses and growth: relationship to receptor estrogen binding by uterine nuclei. , 1975, Endocrinology.
[109] W. Holzgreve,et al. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. , 1999, Menopause.
[110] C. Christiansen,et al. Efficacy and acceptability of intranasal 17 β-oestradiol for menopausal symptoms: randomised dose-response study , 1999, The Lancet.
[111] I. Schiff. The effects of progestins on vasomotor flushes. , 1982, The Journal of reproductive medicine.
[112] L. Mattsson,et al. Metabolic Effects of Continuous Estradiol-Progestin Therapy in Postmenopausal Women , 1989, Obstetrics and gynecology.
[113] J. Studd,et al. Dose-ranging studies of a novel intranasal estrogen replacement therapy. , 2001, Maturitas.
[114] C. Shively,et al. Oral contraceptives, lipoproteins, and atherosclerosis. , 1990, American journal of obstetrics and gynecology.
[115] B. Hazard,et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. , 1991, The Journal of clinical endocrinology and metabolism.
[116] L. Shulman,et al. Safety and efficacy of a continuous once-a-week 17beta-estradiol/levonorgestrel transdermal system and its effects on vasomotor symptoms and endometrial safety in postmenopausal women: the results of two multicenter, double-blind, randomized, controlled trials. , 2002, Menopause.
[117] A. Järvinen,et al. Absorption and bioavailability of oestradiol from a gel, a patch and a tablet. , 1999, Maturitas.
[118] H. Hauner,et al. Demonstration of estrogen receptor subtypes α and β in human adipose tissue: influences of adipose cell differentiation and fat depot localization , 2001, Molecular and Cellular Endocrinology.
[119] G. Watt,et al. Different Effects of Oral and Transdermal Hormone Replacement Therapies on Factor IX, APC Resistance, t-PA, PAI and C-reactive Protein , 2001, Thrombosis and Haemostasis.
[120] M. Blombäck,et al. Effects of vaginally administered high estradiol doses on hormonal pharmacokinetics and hemostasis in postmenopausal women. , 2002, Fertility and sterility.
[121] D. Mishell,et al. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. , 1985, American journal of obstetrics and gynecology.
[122] E. Diczfalusy,et al. Pharmacokinetics and biotransformation of orally administered oestrone sulphate and oestradiol valerate in post-menopausal women. , 1990, Maturitas.
[123] M. Bixo,et al. Negative mood changes during hormone replacement therapy: a comparison between two progestogens. , 2000, American journal of obstetrics and gynecology.
[124] V. Wynn,et al. Comparison of transdermal and oral estrogen‐progestin replacement therapy: Effects on serum lipids and lipoproteins , 1992 .
[125] N. Sänger,et al. Formation of 7&agr;-methyl-ethinyl estradiol during treatment with tibolone , 2002, Menopause.
[126] H. Verheul,et al. Pharmacokinetics of tibolone in early and late postmenopausal women. , 2002, British journal of clinical pharmacology.
[127] L. Andersson,et al. Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. , 1983, Biochemical pharmacology.
[128] B. Sherwin. The impact of different doses of estrogen and progestin on mood and sexual behavior in postmenopausal women. , 1991, The Journal of clinical endocrinology and metabolism.
[129] C. Gerlinger,et al. A pharmacokinetic study with a low-dose oral contraceptive containing 20 μg ethinylestradiol plus 100 μg levonorgestrel , 2002 .
[130] D. Archer,et al. A randomized comparison of continuous combined transdermal delivery of estradiol-norethindrone acetate and estradiol alone for menopause , 1999 .
[131] J. Blümel,et al. Effects of transdermal estrogens on endothelial function in postmenopausal women with coronary disease , 2003, Climacteric : the journal of the International Menopause Society.
[132] I. Jialal,et al. Differential effects of oral versus transdermal estrogen replacement therapy on C-reactive protein in postmenopausal women. , 2003, Journal of the American College of Cardiology.
[133] B. Komm,et al. Estrogenic effects of 7α-methyl-17α-ethynylestradiol: a newly discovered tibolone metabolite , 2002, Steroids.
[134] R. Pijnenborg,et al. Comparative study of the estrogenic effect of ethinylestradiol and mestranol on the endometrium. , 1976, Contraception.
[135] D. Sturdee,et al. Endometrial safety of a transdermal sequential estradiol–levonorgestrel combination , 2002, Climacteric : the journal of the International Menopause Society.
[136] C. Furberg,et al. Estrogen Replacement Therapy and Progression of Intimal-Medial Thickness in the Carotid Arteries of Postmenopausal Women , 1995 .
[137] M. Blankenstein,et al. Effects of low-dose oral and transdermal estrogen replacement therapy on hemostatic factors in healthy postmenopausal women: a randomized placebo-controlled study. , 2003, American journal of obstetrics and gynecology.
[138] F. Helmond,et al. Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. , 2000, Fertility and sterility.
[139] C. Furberg,et al. Effect of Estrogen Plus Progestin on Progression of Carotid Atherosclerosis in Postmenopausal Women With Heart Disease: HERS B-Mode Substudy , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[140] C. Fletcher,et al. The effects of hormone implants on serum lipoproteins and steroid hormones in bilaterally oophorectomised women. , 1984, Acta endocrinologica.
[141] W. Pardridge,et al. Differential permeability of uterine and liver vascular beds to estrogens and estrogen conjugates. , 1984, The Journal of clinical endocrinology and metabolism.
[142] C. Kluft,et al. Importance of levonorgestrel dose in oral contraceptives for effects on coagulation , 1999, The Lancet.
[143] E. Gurpide,et al. Influence of endometrial 17 beta-hydroxysteroid dehydrogenase activity on the binding of estradiol to receptors. , 1981, The Journal of clinical endocrinology and metabolism.
[144] G. Hammond,et al. Serum distribution of the major metabolites of norgestimate in relation to its pharmacological properties. , 2003, Contraception.
[145] T. Clarkson. The new conundrum: do estrogens have any cardiovascular benefits? , 2002, International journal of fertility and women's medicine.
[146] R. Busse,et al. Sex Steroids Used in Hormonal Treatment Increase Vascular Procoagulant Activity by Inducing Thrombin Receptor (PAR-1) Expression: Role of the Glucocorticoid Receptor , 2001, Circulation.
[147] D. Desiderio,et al. Sedative and hypnotic effects of oral administration of micronized progesterone may be mediated through its metabolites. , 1989, American journal of obstetrics and gynecology.
[148] S. Christau,et al. A double‐blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms , 1998, British journal of obstetrics and gynaecology.
[149] M. Sambhi,et al. Biologic Effects of Various Doses of Ethinyl Estradiol in Postmenopausal Women , 1982, Obstetrics and gynecology.
[150] H. Kuhl,et al. Pharmacokinetics of oestrogens and progestogens. , 1990, Maturitas.
[151] H. Judd,et al. Comparison of the impact of transdermal versus oral estrogens on biliary markers of gallstone formation in postmenopausal women. , 1998, The Journal of clinical endocrinology and metabolism.
[152] T. Aydın,et al. Carotid intima-media thickness in surgical menopause: women who received HRT versus who did not. , 2002, Maturitas.
[153] L. Enk,et al. A comparison of the effects of ethinyl estradiol and estradiol valerate on serum and lipoprotein lipids. , 1988, Maturitas.
[154] W. Collins,et al. Randomized, double-blind, dose-ranging study of the endometrial effects of a vaginal progesterone gel in estrogen-treated postmenopausal women. , 1997, American journal of obstetrics and gynecology.
[155] R. Lobo,et al. A randomized comparison of nonoral estradiol delivery in postmenopausal women. , 1988, American journal of obstetrics and gynecology.
[156] N. Crona,et al. A multicentre comparative study of serum lipids and lipoproteins in four groups of oral combined contraceptive users and a control group of IUD users. World Health Organization. Task Force on Oral Contraceptives. , 1988, Contraception.
[157] G. Merino,et al. Tissue localization of radioactive chlormadinone acetate and progesterone in the human , 1970 .
[158] K. Ryan,et al. Plasma estriol and its conjugates following oral and vaginal administration of estriol to postmenopausal women: correlations with gonadotropin levels. , 1980, American journal of obstetrics and gynecology.
[159] W. Kuhnz,et al. Systemic availability of levonorgestrel after single oral administration of a norgestimate-containing combination oral contraceptive to 12 young women. , 1994, Contraception.
[160] Robert Selzer,et al. Estrogen in the Prevention of Atherosclerosis , 2001, Annals of Internal Medicine.
[161] F. Riphagen. Intrauterine application of progestins in hormone replacement therapy: a review , 2000, Climacteric : the journal of the International Menopause Society.
[162] S. Helgason. Estrogen Replacement Therapy after the Menopause , 1982 .
[163] R. Francis,et al. The Effect of Estrogen Dose on Postmenopausal Bone Loss , 1983 .
[164] P. Giangrande,et al. The A and B isoforms of the human progesterone receptor: two functionally different transcription factors encoded by a single gene. , 1999, Recent progress in hormone research.
[165] Charles Kooperberg,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.
[166] R. Tuimala,et al. A 1-year comparison of the efficacy and clinical tolerance in postmenopausal women of two hormone replacement therapies containing estradiol in combination with either norgestrel or trimegestone , 2001, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.
[167] M. Roger,et al. Profiles of plasma estrogens, progesterone and their metabolites after oral or vaginal administration of estradiol or progesterone. , 1993, Maturitas.
[168] J. Isner,et al. Variable expression of the estrogen receptor in normal and atherosclerotic coronary arteries of premenopausal women. , 1994, Circulation.
[169] Ailsa E Gebbie,et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative Randomized Controlled Trial. Writing Group for the Women's Health Initiative Investigators. JAMA 2002; 288(3): 321-333 , 2002, Journal of Family Planning and Reproductive Health Care.
[170] G. Rosano,et al. The acute effects of sublingual 17beta-estradiol on the cardiovascular system. , 1999, Maturitas.
[171] C. Castelo-Branco,et al. Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone-stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. , 1999, Fertility and sterility.
[172] L. Ignarro,et al. Acute effects of transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women. , 1997, Fertility and sterility.
[173] S. Williams,et al. A study of combined continuous ethinyl estradiol and norethindrone acetate for postmenopausal hormone replacement. , 1990, American journal of obstetrics and gynecology.
[174] P. Touboul,et al. Hormone replacement therapy use is associated with a lower occurrence of carotid atherosclerotic plaques but not with intima-media thickness progression among postmenopausal women. The vascular aging (EVA) study. , 2003, Atherosclerosis.
[175] John Robbins,et al. National cross sectional survey to determine whether the decision to delivery interval is critical in emergency caesarean section , 2004, BMJ : British Medical Journal.
[176] W. Losert,et al. Progestogens with antimineralocorticoid activity. , 1985, Arzneimittel-Forschung.
[177] K. Wahlbeck,et al. Estrogen deficiency in severe postpartum depression: successful treatment with sublingual physiologic 17beta-estradiol: a preliminary study. , 2001, The Journal of clinical psychiatry.
[178] M. Metzler. Metabolism of stilbene estrogens and steroidal estrogens in relation to carcinogenicity , 1984, Archives of Toxicology.
[179] M. Sauer,et al. Pharmacokinetics and endometrial tissue levels of progesterone after administration by intramuscular and vaginal routes: a comparative study. , 1994, Fertility and sterility.
[180] A. Rübig. Drospirenone: a new cardiovascular-active progestin with antialdosterone and antiandrogenic properties. , 2003, Climacteric : the journal of the International Menopause Society.
[181] A. Conney,et al. Functional role of estrogen metabolism in target cells: review and perspectives. , 1998, Carcinogenesis.
[182] W. Braselton,et al. Accumulation of norethindrone and individual metabolites in human plasma during short- and long-term administration of a contraceptive dosage. , 1979, American journal of obstetrics and gynecology.
[183] F. al-Azzawi,et al. Acceptability and patterns of endometrial bleeding in estradiol-based HRT regimens: a comparative study of cyclical sequential combinations of trimegestone or norethisterone acetate , 2001, Climacteric : the journal of the International Menopause Society.
[184] I. Godsland. Effects of postmenopausal hormone replacement therapy on lipid, lipoprotein, and apolipoprotein (a) concentrations: analysis of studies published from 1974-2000. , 2001, Fertility and sterility.
[185] Moore Ra. Livial: a review of clinical studies. , 1999 .
[186] E. Cicinelli,et al. Nasally-administered progesterone: comparison of ointment and spray formulations. , 1991, Maturitas.
[187] M. Pistis,et al. Efficacy and safety of oral and transdermal hormonal replacement treatment containing levonorgestrel. , 2002, Maturitas.
[188] A. Messenger,et al. The Distribution of Estrogen Receptor β Is Distinct to That of Estrogen Receptor α and the Androgen Receptor in Human Skin and the Pilosebaceous Unit , 2003 .
[189] F. Petraglia,et al. Benefits and risks of different hormonal replacement therapies in post-menopausal women. , 1986, Maturitas.
[190] D. Leysen,et al. Tibolone is not converted by human aromatase to 7α-methyl-17α-ethynylestradiol (7α-MEE): Analyses with sensitive bioassays for estrogens and androgens and with LC-MSMS , 2003, Steroids.
[191] A. Johnston. Estrogens--pharmacokinetics and pharmacodynamics with special reference to vaginal administration and the new estradiol formulation--Estring. , 1996, Acta obstetricia et gynecologica Scandinavica. Supplement.
[192] A. Basdevant,et al. Effects of nomegestrol acetate (5 mg/d) on hormonal, metabolic and hemostatic parameters in premenopausal women. , 1991, Contraception.
[193] R. Druckmann. Progestins and their effects on the breast. , 2003, Maturitas.
[194] L. Ignarro,et al. Effects of short-term transdermal estradiol administration on plasma levels of nitric oxide in postmenopausal women. , 1998, Fertility and sterility.
[195] H. Burger. Hormone replacement therapy in the post-Women's Health Initiative era. Report a a meeting held in Funchal, Madeira, February 24-25, 2003. , 2003, Climacteric : the journal of the International Menopause Society.
[196] J. Kitawaki,et al. Aromatization of norethindrone to ethynylestradiol in human adult liver. , 1986 .
[197] M. Whitehead,et al. The Role and Use of Progestogens , 1990, Obstetrics and gynecology.
[198] L. Wiseman,et al. Transdermal Estradiol/Norethisterone , 1994 .
[199] D. Hahn,et al. A comparison of the potencies and activities of progestogens used in contraceptives. , 1987, Contraception.
[200] V. de Leo,et al. Effect of low-dose transdermal E2/NETA on the reduction of postmenopausal bone loss in women , 2003, Menopause.
[201] H. Adami,et al. Low-potency oestrogen and risk of endometrial cancer: a case-control study , 1999, The Lancet.
[202] D. Molloy,et al. The effects of different types and doses of oestrogen replacement therapy on clinic and ambulatory blood pressure and the renin-angiotensin system in normotensive postmenopausal women. , 1999, Journal of hypertension.
[203] D. Mishell,et al. Comparison of pharmacodynamic properties of various estrogen formulations. , 1982, American journal of obstetrics and gynecology.
[204] R. Paoletti,et al. The Menopause and Postmenopause , 1980, Springer Netherlands.
[205] B. Wren. Progesterone creams: do they work? , 2003, Climacteric : the journal of the International Menopause Society.
[206] F. Stanczyk,et al. Endothelin levels decrease after oral and nonoral estrogen in postmenopausal women with increased cardiovascular risk factors. , 1997, Fertility and sterility.
[207] N. Watson,et al. Comparison of the pharmacokinetics of crinone 8% administered vaginally versus Prometrium administered orally in postmenopausal women(3). , 2000, Fertility and sterility.
[208] R. Fanchin,et al. Transvaginal Administration of Progesterone , 1997, Obstetrics and gynecology.
[209] E. Gurpide,et al. Human endometrial 3β-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD 14) , 1993, The Journal of Steroid Biochemistry and Molecular Biology.
[210] G. Heimer,et al. Enterohepatic recirculation of oestriol: inhibition by activated charcoal. , 1986, Acta endocrinologica.
[211] J. Tapanainen,et al. Intrauterine 10μg and 20μg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response , 2002, BJOG : an international journal of obstetrics and gynaecology.
[212] D. Reboussin,et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. , 2000, The New England journal of medicine.
[213] Hormone replacement therapy and risk of venous thromboembolism: population based case-control study. , 1997, BMJ.
[214] M. Hashida,et al. The transport of a drug to the cerebrospinal fluid directly from the nasal cavity: the relation to the lipophilicity of the drug. , 1991, Chemical & pharmaceutical bulletin.
[215] J. Studd,et al. The dose–response of percutaneous oestradiol implants on the skeletons of postmenopausal women , 1994, British journal of obstetrics and gynaecology.
[216] P. Bonnet,et al. The pharmacological profile of TX 066 (17 alpha-acetoxy-6-methyl-19-nor-4,6-pregna-diene-3,20-dione), a new oral progestative. , 1983, Arzneimittel-Forschung.
[217] D. Marshall,et al. Dose-dependent response of FSH, flushes and urinary calcium to oestrogen. , 1982, Maturitas.
[218] S. Sasson,et al. Molecular and kinetic basis for the mixed agonist/antagonist activity of estriol. , 1997, Molecular endocrinology.
[219] J. Studd,et al. A study to evaluate serum and urinary hormone levels following short and long term administration of two regimens of progesterone cream in postmenopausal women , 2000, BJOG : an international journal of obstetrics and gynaecology.
[220] G. Vooijs,et al. Review of the endometrial safety during intravaginal treatment with estriol. , 1995, European journal of obstetrics, gynecology, and reproductive biology.
[221] K. Fotherby,et al. New progestogens in oral contraception. , 1994, Contraception.
[222] S. Koide,et al. Nestorone®: a progestin with a unique pharmacological profile , 2000, Steroids.
[223] C. Stehouwer,et al. Effects of Transdermal and Oral Oestrogen Replacement Therapy on C-Reactive Protein Levels in Postmenopausal Women: A Randomised, Placebo-Controlled Trial , 2002, Thrombosis and Haemostasis.
[224] P. Dastidar,et al. Combined oestrogen-progestin replacement therapy prevents atherosclerosis in postmenopausal women. , 1995, Maturitas.
[225] A. Reutens,et al. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women , 2003, Clinical endocrinology.
[226] O. Heikinheimo,et al. Transdermal absorption of the progestin ST-1435: therapeutic serum steroid concentrations and high excretion of the steroid in saliva. , 1991, Contraception.
[227] H. S. Choi,et al. Estrogen receptor, a common interaction partner for a subset of nuclear receptors. , 1998, Molecular endocrinology.
[228] T. Meade,et al. Hormone Replacement Therapy and Haemostatic Function , 1997, Thrombosis and Haemostasis.
[229] L. Hamberger,et al. Is the contraceptive effect of 300 μg of norethisterone mainly peripheral or central , 1992 .
[230] A. Ferenczy,et al. Endometrial safety and bleeding patterns during a 2-year study of 1 or 2 mg 17 beta-estradiol combined with sequential 5-20 mg dydrogesterone. , 2002 .
[231] H. Kuhl,et al. Oral contraceptives containing 20 or 30 micrograms ethinylestradiol and 150 micrograms desogestrel: pharmacokinetics and pharmacodynamic parameters. , 1991, Hormone research.
[232] E. Oger,et al. Differential effects of oral and transdermal postmenopausal estrogen replacement therapies on C-reactive protein. , 2003, Thrombosis and haemostasis.
[233] S. Ménard,et al. Proliferation of breast carcinoma during menstrual phases , 1998, The Lancet.
[234] J. Simon,et al. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. , 2003, American journal of obstetrics and gynecology.
[235] J. Thijssen. Overview on the effects of progestins on bone. , 2003, Maturitas.
[236] R. Boyd,et al. The Effect of Food on the Bioavailability of Norethindrone and Ethinyl Estradiol from Norethindrone Acetate/Ethinyl Estradiol Tablets Intended for Continuous Hormone Replacement Therapy , 2003, Journal of clinical pharmacology.
[237] B. Düsterberg,et al. Pharmacokinetic and pharmacological features of oestradiol valerate. , 1982, Maturitas.
[238] H. B. Leonetti,et al. Topical progesterone cream has an antiproliferative effect on estrogen-stimulated endometrium. , 2003, Fertility and sterility.
[239] Larry Z. Shen,et al. Steady‐State Bioavailability of Estradiol from Two Matrix Transdermal Delivery Systems, Alora and Climara , 1998, Menopause.
[240] J. Reginster,et al. Plasma estradiol concentrations and pharmacokinetics following transdermal application of Menorest 50 or Systen (Evorel) 50. , 1997, Maturitas.
[241] M. Cazzaniga,et al. Effect of Transdermal Estradiol and Oral Conjugated Estrogen on C-Reactive Protein in Retinoid-Placebo Trial in Healthy Women , 2002, Circulation.
[242] F. Sacks,et al. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. , 1994, Journal of lipid research.
[243] O. Ylikorkala,et al. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids. , 1997, International journal of fertility and women's medicine.
[244] S. Yen,et al. Absorption of estrogens from vaginal creams. , 1978, The New England journal of medicine.
[245] C. Castelo-Branco,et al. Tibolone and risk of endometrial polyps: a prospective, comparative study with hormone therapy , 2003, Menopause.
[246] V. Möbus,et al. Dihydrospirorenone (ZK30595): a novel synthetic progestagen--characterization of binding to different receptor proteins. , 1992, Contraception.
[247] H. Judd,et al. Treatment of hot flashes with transdermal estradiol administration. , 1985, The Journal of clinical endocrinology and metabolism.
[248] L. Mattsson,et al. A clinical evaluation of treatment with estriol vaginal cream versus suppository in postmenopausal women , 1983, Acta obstetricia et gynecologica Scandinavica.
[249] L. García-Rodríguez,et al. Hormone replacement therapy and incidence of acute myocardial infarction. A population-based nested case-control study. , 2000, Circulation.
[250] W. Jusko,et al. Differences in pharmacokinetics and comparative bioavailability between premarin® and estratab® in healthy postmenopausal women , 1994 .
[251] R. Rebar,et al. A short study in the treatment of hot flashes with buccal administration of 17-beta estradiol. , 2004, Maturitas.
[252] N. Siseles,et al. Once and twice a week transdermal estradiol delivery systems: clinical efficacy and plasma estrogen levels. , 1998, Climacteric : the journal of the International Menopause Society.
[253] E. Johansson,et al. Influence of food on oestriol blood levels. , 1984, Maturitas.
[254] I. Fraser,et al. Estradiol-delivering vaginal rings for hormone replacement therapy. , 1999, American journal of obstetrics and gynecology.
[255] I. Rauramo,et al. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. , 2001, Fertility and sterility.
[256] Dominique Mottier,et al. Differential Effects of Oral and Transdermal Estrogen/Progesterone Regimens on Sensitivity to Activated Protein C Among Postmenopausal Women: A Randomized Trial , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[257] W. Koenig,et al. Double blind, randomized study of estradiol replacement therapy on markers of inflammation, coagulation and fibrinolysis. , 2003, Atherosclerosis.
[258] S. Longo,et al. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. , 1999, Obstetrics and gynecology.
[259] C. Kitchens,et al. Metabolic and Hormonal Effects of 25‐mg and 50‐mg 17β‐Estradiol Implants in Surgically Menopausal Women , 1987, Obstetrics and gynecology.
[260] E. Quebe-Fehling,et al. Dose proportionality study of four doses of an estradiol transdermal system, Estradot. , 2003, Maturitas.
[261] R. Day,et al. Pharmacokinetics of estradiol, progesterone, testosterone and dehydroepiandrosterone after transbuccal administration to postmenopausal women , 2003, Climacteric : the journal of the International Menopause Society.
[262] M. Jondet,et al. Chlormadinone acetate versus micronized progesterone in the sequential combined hormone replacement therapy of the menopause. , 2001, Maturitas.
[263] K. Takahashi,et al. Efficacy and safety of oral estriol for managing postmenopausal symptoms. , 2000, Maturitas.
[264] J. Studd,et al. Natural progesterone and antihypertensive action , 1985, British medical journal.
[265] R Krattenmacher,et al. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. , 2000, Contraception.
[266] L. Patterson,et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy , 2004, Journal of Family Planning and Reproductive Health Care.
[267] W. Schoonen,et al. Hormonal properties of norethisterone, 7α-methyl-norethisterone and their derivatives , 2000, The Journal of Steroid Biochemistry and Molecular Biology.
[268] Susan R. Johnson,et al. Effects of Estrogen or Estrogen/ Progestin Regimens on Heart Disease Risk Factors in Postmenopausal Women: The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial , 1995 .
[269] E. Oger,et al. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk , 2003, The Lancet.
[270] M. Nissilä,et al. Pharmacokinetics of estradiol valerate and medroxyprogesterone acetate in different age groups of postmenopausal women. , 2004, Maturitas.
[271] L. Mattsson,et al. Vaginal administration of low-dose oestradiol--effects on the endometrium and vaginal cytology. , 1989, Maturitas.
[272] L. Dibbelt,et al. Pharmacokinetics of levonorgestrel and ethinylestradiol in 14 women during three months of treatment with a tri-step combination oral contraceptive: serum protein binding of levonorgestrel and influence of treatment on free and total testosterone levels in the serum. , 1993, Contraception.
[273] L. Cardozo,et al. Oestriol in the treatment of postmenopausal urgency: a multicentre study. , 1993, Maturitas.
[274] H. Nelson,et al. Postmenopausal Estrogen Replacement and Risk for Venous Thromboembolism , 2002, Annals of Internal Medicine.
[275] J. Foidart,et al. Randomized Comparison of Intranasal and Transdermal Estradiol , 2000, Obstetrics and gynecology.
[276] R. Eastell,et al. The impact of subcutaneous oestradiol implants on biochemical markers of bone turnover and bone mineral density in postmenopausal women , 2002, BJOG : an international journal of obstetrics and gynaecology.
[277] F. Speizer,et al. A Prospective, Observational Study of Postmenopausal Hormone Therapy and Primary Prevention of Cardiovascular Disease , 2000, Annals of Internal Medicine.
[278] N. Siddle,et al. Dose dependent effects of oral progesterone on the oestrogenised postmenopausal endometrium. , 1983, British medical journal.
[279] N. Crona,et al. A Comparison between Effects of Estradiol Valerate and Low Dose Ethinyl Estradiol on Haemostasis Parameters , 1989, Thrombosis and Haemostasis.
[280] U. Raju,et al. Serum Estradiol‐Binding Profiles in Postmenopausal Women Undergoing Three Common Estrogen Replacement Therapies: Associations With Sex Hormone‐Binding Globulin, Estradiol, and Estrone Levels* , 2000, Menopause.
[281] H. Uemura,et al. Biological Effects of Hormone Replacement Therapy in Relation to Serum Estradiol Levels , 2001, Hormone Research in Paediatrics.
[282] G. Heimer. ESTRIOL IN THE POSTMENOPAUSE , 1987, Acta obstetricia et gynecologica Scandinavica. Supplement.
[283] Daniel B. Williams,et al. Intranasal hormone replacement therapy , 2003, Menopause.
[284] M. Sambhi,et al. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. , 1980, The Journal of clinical endocrinology and metabolism.
[285] L. Lagasse,et al. Effect of megestrol acetate on flushing and bone metabolism in post-menopausal women. , 1981, Maturitas.
[286] M. Oriowo,et al. A comparison of the pharmacokinetic properties of three estradiol esters. , 1980, Contraception.
[287] W. Onatra,et al. Changes in normal lipid profile of menopausal women with combined hormone replacement therapy. Comparative clinical trial of two hormonal combinations (conjugated estrogens/medroxyprogesterone acetate versus estradiol valerate/cyproterone acetate). , 1999, Maturitas.
[288] S. Cummings,et al. Female sexual dysfunction in postmenopausal women: systematic review of placebo-controlled trials. , 2003, American journal of obstetrics and gynecology.
[289] T. Lesnick,et al. Expression of estrogen receptor isoforms α and β messenger RNA in vaginal tissue of premenopausal and postmenopausal women , 2001 .
[290] T. Strandberg,et al. Differing effects of oral and transdermal hormone replacement therapy on cardiovascular risk factors in healthy postmenopausal women. , 2003, The American journal of cardiology.
[291] J. Dunn,et al. Transport of steroid hormones: binding of 21 endogenous steroids to both testosterone-binding globulin and corticosteroid-binding globulin in human plasma. , 1981, The Journal of clinical endocrinology and metabolism.
[292] R. Punnonen,et al. Serum oestriol, oestrone and oestradiol concentrations during oral oestriol succinate treatment in ovariectomized women. , 1978, Maturitas.
[293] A. Akkad,et al. Continuous combined hormone replacement therapy compared with tibolone. , 1999, Obstetrics and gynecology.
[294] D. Barlow,et al. Long-Term Hormone Implant Therapy—Hormonal and Clinical Effects , 1986, Obstetrics and gynecology.
[295] P. Ortiz de Montellano,et al. Self-catalyzed inactivation of hepatic cytochrome P-450 by ethynyl substrates. , 1980, The Journal of biological chemistry.
[296] E. Oger,et al. The effects of transdermal and oral estrogen/progesterone regimens on free and total protein S in postmenopausal women. , 2001, Thrombosis and haemostasis.
[297] E. Nikkilä,et al. Post-menopausal hormone replacement therapy: effects of progestogens on serum lipids and lipoproteins. A review. , 1986, Maturitas.
[298] C. Martucci,et al. Uterine estrogen receptor binding of catecholestrogens and of estetrol (1,3,5(10)-estratriene-3,15α,16α,17β-tetrol) , 1976, Steroids.
[299] C. Anderson,et al. Pharmacokinetics of percutaneous estradiol: A crossover study using a gel and a transdermal system in comparison with oral micronized estradiol , 1991, Obstetrics and gynecology.
[300] A. O’Sullivan,et al. The route of estrogen replacement therapy confers divergent effects on substrate oxidation and body composition in postmenopausal women. , 1998, The Journal of clinical investigation.
[301] R. Kraemer,et al. Variability of serum estrogens among postmenopausal women treated with the same transdermal estrogen therapy and the effect on androgens and sex hormone binding globulin. , 2003, Fertility and sterility.
[302] S. Cummings,et al. Tibolone for postmenopausal women: systematic review of randomized trials. , 2002, The Journal of clinical endocrinology and metabolism.
[303] D. McDonnell,et al. The Estrogen Receptor -isoform (er) of the Human Estrogen Receptor Modulates Er␣ Transcriptional Activity and Is a Key Regulator of the Cellular Response to Estrogens and Antiestrogens* , 2022 .
[304] E. Farish,et al. Effects on climacteric symptoms, bone and lipoprotein metabolism of hormone replacement therapy delivered by estradiol-releasing intravaginal rings: a pilot study , 2003, Climacteric : the journal of the International Menopause Society.
[305] K. Michaëlsson,et al. Use of low potency estrogens does not reduce the risk of hip fracture. , 2002, Bone.
[306] W. Schoonen,et al. Receptor profiling and endocrine interactions of tibolone , 2003, Steroids.
[307] F. Guengerich,et al. Inhibition of oral contraceptive steroid-metabolizing enzymes by steroids and drugs. , 1990, American journal of obstetrics and gynecology.
[308] A. Volpe,et al. Transvaginal estriol administration in postmenopausal women: a double blind comparative study of two different doses. , 1995, Maturitas.
[309] D. Back,et al. Comparative pharmacokinetics of levonorgestrel and ethinyloestradiol following intravenous, oral and vaginal administration. , 1987, Contraception.
[310] P. Schofield,et al. A study of hormone replacement therapy in postmenopausal women with ischaemic heart disease: the Papworth HRT Atherosclerosis Study , 2002, BJOG : an international journal of obstetrics and gynaecology.
[311] O. Ylikorkala,et al. Administration of transdermal estrogen without progestin increases the capacity of plasma and serum to stimulate prostacyclin production in human vascular endothelial cells. , 2000, Fertility and sterility.
[312] C. Martucci,et al. New Concepts of Estrogenic Activity: the Role of Metabolites in the Expression of Hormone Action , 1980 .
[313] D. Crook,et al. The metabolic consequences of treating postmenopausal women with non‐oral hormone replacement therapy , 1997, British journal of obstetrics and gynaecology.
[314] R. Cannon,et al. Divergent effects of hormone therapy on serum markers of inflammation in postmenopausal women with coronary artery disease on appropriate medical management. , 2000, Journal of the American College of Cardiology.
[315] M. Anthony,et al. A comparison of tibolone and conjugated equine estrogens effects on coronary artery atherosclerosis and bone density of postmenopausal monkeys. , 2001, The Journal of clinical endocrinology and metabolism.
[316] I. Fraser,et al. A comparative study of safety and efficacy of continuous low dose oestradiol released from a vaginal ring compared with conjugated equine oestrogen vaginal cream in the treatment of postmenopausal urogenital atrophy , 1996, British journal of obstetrics and gynaecology.
[317] H. Croxatto,et al. Pharmacokinetics and bioavailability of ST 1435 administered by different routes. , 1993, Contraception.
[318] Kazushi Watanabe,et al. Different effects of oral and transdermal estrogen replacement therapy on matrix metalloproteinase and their inhibitor in postmenopausal women. , 2003, Arteriosclerosis, thrombosis, and vascular biology.
[319] O. Chevallier,et al. Oral 17&bgr;-estradiol (1 mg) continuously combined with dydrogesterone improves the serum lipid profile of postmenopausal women , 2002, Menopause.
[320] B. Bhavnani,et al. Interaction of ring B unsaturated estrogens with estrogen receptors of human endometrium and rat uterus , 1991, Steroids.